About the Company
decibel therapeutics is a hearing company focused on discovering and developing new medicines to protect, repair and restore hearing. hearing loss is the most prevalent form of sensory impairment. it is estimated that 50 million people in the u.s., and 360 million people worldwide, suffer from some type of hearing loss. hearing disorders affect people of all ages and can have a profound impact on quality of life. by combining recent innovations in hearing science with leading diagnostic tools, biological insights, modeling and therapeutic delivery techniques, decibel is pioneering a comprehensive approach to defining and treating the underlying biological causes of hearing disorders, and developing a pipeline of breakthrough drugs targeted to specific indications and patients. founded by the world’s preeminent experts in inner ear biology and hearing disorders, decibel therapeutics was launched in 2015 by third rock ventures and sr one and is headquartered in boston, mass. for more inf
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $DBTX News
Decibel Therapeutics gets grant for hypertonic pharmaceutical composition for anti-platinum chemoprotection
Discover the groundbreaking patent by Decibel Therapeutics Inc for hypertonic pharmaceutical compositions with anti-platinum agents to prevent ototoxicity. Learn about the innovative methods and ...
Regeneron finalizes acquisition of Decibel Therapeutics, enhancing gene therapy portfolio
Regeneron (NASDAQ:REGN) Pharmaceuticals, Inc. (NASDAQ:REGN) announced on Monday that it has successfully completed the acquisition of Decibel Therapeutics, Inc., a move that strengthens Regeneron ...
Decibel Therapeutics stock rallies as Regeneron moves to buy the biotech company
Decibel Therapeutics Inc. stock was up 85% in premarket trades on Wednesday after Regeneron Pharmaceuticals Inc. said it would pay $4 a share for the Boston-based clinical-stage biotechnology ...
Decibel Therapeutics Inc.
Wall Street is sure the stock market is going higher, thanks to blockbuster earnings last week from Nvidia and the promise of Artificial Intelligence. But will the Fed spoil the party?
Regeneron dials up in gene therapy with Decibel deal
Regeneron has agreed a $109 million deal to acquire Decibel Therapeutics and its early-stage gene therapy for a form of congenital deafness, several years after forming a partnership to tackle ...
DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. The company ...
RLAY Relay Therapeutics, Inc.
Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule ...
TG Therapeutics Inc TGTX
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...
Plc Gsk's Net Worth
Plc Gsk has an estimated net worth of $9.11 Billion. This is based on reported shares across multiple companies, which include Wave Life Sciences Ltd., CVRx, Inc., Lyell Immunopharma, Inc ...
Agile Therapeutics: Q4 Earnings Snapshot
PRINCETON, N.J. — PRINCETON, N.J. — Agile Therapeutics Inc. (AGRX) on Thursday reported a loss of $4.5 million in its fourth quarter. On a per-share basis, the Princeton, New Jersey-based ...
Decibel Therapeutics
This page shows the latest Decibel Therapeutics news and features for those working in and with pharma, biotech and healthcare. Hearing disorders specialist Decibel Therapeutics has expanded its ...
Loading the latest forecasts...